Extraction of lycopene from tomato pomace and its protective effects on renal injury in diabetic rats

XIE, Rong; ZHANG, Heping; LIU, Xiaohui; LIU, Jiali; LI, Qinyun

doi:10.1590/fst.116621

Acessibilidade / Reportar erro

Brasil

Food Science and Technology

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Original Article • Food Sci. Technol 42 • 2022 • https://doi.org/10.1590/fst.116621 copy

Extraction of lycopene from tomato pomace and its protective effects on renal injury in diabetic rats

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstract

The aim of this study was to investigate the protective effects of lycopene from tomato pomace on renal injury in diabetic rats. Lycopene was extracted from tomato pomace. The rats were divided into control, model and 10, 20 and mg/kg lycopene groups. The diabetic nephropathy model was constructed in the latter four groups. Then, the latter three groups were treated with 10, 20 and mg/kg lycopene, respectively. After four weeks of treatment, compared with the model group, in 20 and 40 mg/kg lycopene groups the serum fasting plasma glucose level was decreased (P < 0.05), the fasting insulin level was increased (P < 0.05), the renal index and 24-h urinary protein level were decreased (P < 0.05), the blood urea nitrogen and serum creatinine levels were decreased (P < 0.05), the renal tissue superoxide dismutase and glutathione peroxidase levels were increased (P < 0.05), the renal tissue malondialdehyde level was decreased (P < 0.05), and the serum tumor necrosis factor α, interleukin 6 and hypersensitive C-reactive protein levels were decreased (P < 0.05). In conclusion, lycopene from tomato pomace can alleviate renal injury in diabetic rats. The mechanism may be related to the resistance of oxidative stress and inflammatory response.

Keywords:
lycopene; diabetes; renal injury; oxidative stress; inflammatory response

Group	n	FBG (mmol/L)	FINS (mIU/L)
Control	12	5.47 ± 1.67	33.17 ± 5.36
Model	12	24.90 ± 4.89^a a P < 0.05 compared with control group;	19.69 ± 2.81^a
10 mg/kg lycopene	12	22.19 ± 3.15^a	22.11 ± 3.30^a
20 mg/kg lycopene	12	15.32 ± 3.05^a^b b P < 0.05 compared with model group; ^c	25.16 ± 3.99^ab
40 mg/kg lycopene	12	11.89 ± 2.62^ab^c c P < 0.05 compared with 10 mg/kg lycopene group; ^d	28.66 ± 2.81^abc^d d P < 0.05 compared with 10 mg/kg lycopene group. FBG, fasting plasma glucose; FINS, fasting insulin.
F		58.003	23.940
P		0.000	0.000

Group	n	Renal index (mg/g)	24h UP (mg)
Control	12	2.83 ± 0.21	8.82 ± 1.56
Model	12	4.66 ± 0.65^a a P < 0.05 compared with control group;	28.05 ± 5.19^a
10 mg/kg lycopene	12	4.28 ± 0.53^a	24.40 ± 3.28^a
20 mg/kg lycopene	12	3.84 ± 0.43^a^b b P < 0.05 compared with model group;	20.64 ± 4.06^ab
40 mg/kg lycopene	12	3.37 ± 0.42^ab^c c P < 0.05 compared with 10 mg/kg lycopene group; ^d	11.78 ± 1.60^abc^d d P < 0.05 compared with 10 mg/kg lycopene group. 24h UP, 24-h urinary protein.
F		26.792	58.917
P		0.000	0.000

Group	n	BUN (mmol/L)	Scr (μmol/L)
Control	12	5.82 ± 0.78	23.34 ± 2.05
Model	12	18.94 ± 2.54^a a P < 0.05 compared with control group;	42.90 ± 4.65^a
10 mg/kg lycopene	12	15.43 ± 2.87^a^b b P < 0.05 compared with model group;	40.12 ± 5.90^a
20 mg/kg lycopene	12	12.17 ± 2.04^ab^c c P < 0.05 compared with 10 mg/kg lycopene group;	34.47 ± 4.98^ab
40 mg/kg lycopene	12	9.84 ± 1.56^abcd	30.27 ± 4.04^abc^d d P < 0.05 compared with 10 mg/kg lycopene group. BUN, blood urea nitrogen; Scr, serum creatinine.
F		79.160	36.651
P		0.000	0.000

Group	n	SOD (U/mg prot)	GSH-Px (U/mg prot)	MDA (nmol/mg prot)
Control	12	55.37 ± 8.04	48.09 ± 7.37	2.82 ± 0.43
Model	12	25.94 ± 4.33^a a P < 0.05 compared with control group;	18.49 ± 3.41^a	13.30 ± 2.87^a
10 mg/kg lycopene	12	30.20 ± 6.28^a	22.37 ± 4.37^a	11.38 ± 3.29^a
20 mg/kg lycopene	12	36.73 ± 3.17^a^b b P < 0.05 compared with model group;	26.18 ± 5.59^ab	6.52 ± 1.66^abc
40 mg/kg lycopene	12	40.17 ± 5.50^ab^c c P < 0.05 compared with 10 mg/kg lycopene group;	33.26 ± 6.84^abc^d d P < 0.05 compared with 10 mg/kg lycopene group. SOD, superoxide dismutase; GSH-Px, glutathione peroxidase; MDA, malondialdehyde.	5.09 ± 1.04^abc
F		44.148	41.206	59.485
P		0.000	0.000	0.000

Group	n	TNF-α (ng/L)	IL-6 (ng/L)	hs-CRP (mg/L)
Control	12	11.05 ± 1.67	12.19 ± 1.38	2.41 ± 0.43
Model	12	18.21 ± 2.44^a a P < 0.05 compared with control group;	21.43 ± 2.06^a	5.67 ± 0.58^a
10 mg/kg lycopene	12	17.36 ± 3.05^a	18.63 ± 1.34^ab	5.03 ± 0.78^a
20 mg/kg lycopene	12	15.73 ± 2.89^a^b b P < 0.05 compared with model group;	16.30 ± 1.06^ab	4.34 ± 0.31^abc
40 mg/kg lycopene	12	14.88 ± 3.05^ab	15.18 ± 1.62^ab^c c P < 0.05 compared with 10 mg/kg lycopene group;	3.98 ± 0.29^abc^d d P < 0.05 compared with 10 mg/kg lycopene group. TNF-α, tumor necrosis factor α; IL-6, interleukin 6; hs-CRP, hypersensitive C-reactive protein.
F		12.328	55.327	89.699
P		0.000	0.000	0.000

Sociedade Brasileira de Ciência e Tecnologia de Alimentos Av. Brasil, 2880, Caixa Postal 271, 13001-970 Campinas SP - Brazil, Tel.: +55 19 3241.5793, Tel./Fax.: +55 19 3241.0527 - Campinas - SP - Brazil
E-mail: revista@sbcta.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] *Corresponding author: zhanghepingnc1@163.com